
Rogelio Apiquian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1268534/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuropsychological screening with TOWI: Performance in 6- to 12-year-old children. Applied Neuropsychology: Child, 2022, 11, 115-124.	1.4	3
2	Similarities and Differences in Associations Between Duration of Untreated Psychosis (DUP) and Demographic, Premorbid, and Symptom Severity Measures in Two Samples of First-Episode Psychosis Patients from Mexico and the United States. Psychiatric Quarterly, 2020, 91, 769-781.	2.1	5
3	Standardization and validity of Chefmania, a video game designed as a cognitive screening test for children. Humanities and Social Sciences Communications, 2020, 7, .	2.9	4
4	Perception of non-imputability in schizophrenia in adolescents of Mexico City. Spanish Journal of Legal Medicine, 2019, 45, 48-51.	0.2	0
5	Cognitive impairment and its improvement after six months in adolescents with schizophrenia. Schizophrenia Research: Cognition, 2019, 17, 100135.	1.3	4
6	Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country. Australian and New Zealand Journal of Psychiatry, 2018, 52, 192-199.	2.3	2
7	A video game for the neuropsychological screening of children. Entertainment Computing, 2017, 20, 1-9.	2.9	11
8	Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia. Schizophrenia Research, 2015, 164, 176-180.	2.0	6
9	Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clÃnicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento. Salud Mental, 2013, 36, 19.	0.3	1
10	Association study of DRD3 gene in schizophrenia in Mexican sib-pairs. Psychiatry Research, 2011, 190, 367-368.	3.3	4
11	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatric Disease and Treatment, 2010, 7, 19.	2.2	12
12	Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophrenia Research, 2009, 112, 181-186.	2.0	36
13	APOE-ε3 and APOE-219G Haplotypes Increase the Risk for Schizophrenia in Sibling Pairs. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 440-444.	1.8	7
14	Variations of rest–Âactivity rhythm and sleep–Âwake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. Biological Rhythm Research, 2008, 39, 69-78.	0.9	18
15	Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. Psychiatry Research, 2007, 153, 209-215.	3.3	14
16	Temperament and character in violent schizophrenic patients. Schizophrenia Research, 2007, 94, 74-80.	2.0	28
17	The P50 auditory evoked potential in violent and non-violent patients with schizophrenia. Schizophrenia Research, 2007, 97, 128-136.	2.0	17
18	Association Study of MAO-A and DRD4 Genes in Schizophrenic Patients with Aggressive Behavior. Neuropsychobiology, 2007, 55, 171-175.	1.9	37

ROGELIO APIQUIAN

#	Article	IF	CITATIONS
19	The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open- label study. BMC Psychiatry, 2005, 5, 22.	2.6	10
20	Violent behavior in schizophrenic patients: relationship with clinical symptoms. Aggressive Behavior, 2005, 31, 511-520.	2.4	41
21	Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone. Neuropsychopharmacology, 2005, 30, 2236-2244.	5.4	28
22	Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism. NeuroImage, 2005, 25, 1197-1204.	4.2	40
23	A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. Schizophrenia Research, 2005, 72, 123-129.	2.0	69
24	Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry, 2004, 4, 12.	2.6	19
25	Premorbid adjustment and violent behavior in schizophrenic patients. Schizophrenia Research, 2004, 69, 143-148.	2.0	15
26	Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. Schizophrenia Research, 2003, 59, 35-39.	2.0	18
27	Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. International Journal of Neuropsychopharmacology, 2003, 6, 403-408.	2.1	19
28	The Mexican first-episode psychotic study: clinical characteristics and premorbid adjustment. Schizophrenia Research, 2002, 53, 161-163.	2.0	13
29	Lack of Association of Apolipoprotein E Polymorphism in Obsessive-Compulsive Disorder. CNS Spectrums, 2001, 6, 978-979, 992.	1.2	4
30	Dopamine D4 Receptor (DRD4) Gene Polymorphism in the First Psychotic Episode. Archives of Medical Research, 2001, 32, 35-38.	3.3	10
31	Personality and Clinical Predictors of Recurrence of Depression. Psychiatric Services, 1999, 50, 376-380.	2.0	53
32	Typical antipsychotics: The threshold doses strategy. European Neuropsychopharmacology, 1996, 6, 199.	0.7	2